Conventional chemotherapeutic regimens designed for aggressive B-cell lymphomas are generally
less effective when applied to mature T-cell or NK-cell lymphomas. The treatment outcome for
relapsed or refractory disease is especially poor.
This is a single centre, prospective, non-randomized, open-label, phase II study to evaluate
the efficacy of pembrolizumab in patients with relapsed or refractory mature T-cell or
NK-cell lymphomas. Patients will receive pembrolizumab 200mg i.v. once every 3 weeks until
disease progression or unacceptable toxicity.
A baseline radiological assessment by positron emission tomography / computed tomography
(PET/CT) scan is obtained before commencement of treatment. Tumor response and progression
are evaluated by physical examination, standard laboratory tests, and PET/CT scan according
to standard criteria. Standard response criteria for non-Hodgkin lymphomas are used for
assessment . PET/CT scan will be done at week 12, week 24, week 36 and every 18 weeks